Summary & Overview
CPT 64611: Bilateral Salivary Gland Injection to Reduce Saliva Production
CPT code 64611 represents bilateral chemical denervation of the parotid and submandibular salivary glands. The procedure is used to reduce saliva production and lower aspiration risk in patients with disorders that cause excessive drooling or sialorrhea. Nationally, this code is relevant to otolaryngology, neurology, rehabilitation medicine, and interventional pain practices because it covers a targeted, minimally invasive intervention with implications for airway safety, oral hygiene, and quality of life.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication provides an overview of coding context and expected sites of service, and summarizes common modifiers and administrative considerations where available. Readers will find clinical context describing the intent and typical delivery of the service, billing and documentation touchpoints, and a summary of payer coverage patterns and benchmark considerations. The content is designed to inform billers, coding specialists, clinicians, and policy analysts about how CPT code 64611 is used, where it is typically performed, and what administrative elements commonly accompany claims. Data not available in the input is acknowledged where applicable.
Billing Code Overview
CPT code 64611 describes administration of a chemical compound to the parotid and submandibular salivary glands bilaterally to decrease saliva production and reduce the risk of aspiration. This procedure involves targeted injection(s) into the major salivary glands to achieve a therapeutic reduction in saliva output.
-
Service type: Therapeutic gland injection for salivary reduction
-
Typical site of service: Ambulatory surgical center or hospital outpatient setting, and may also be performed in specialty outpatient clinics where procedural sedation or monitoring is available
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with severe sialorrhea (excessive drooling) due to neurologic conditions such as Parkinson disease, amyotrophic lateral sclerosis, cerebral palsy, or post-stroke impairment. The patient has recurrent aspiration risk, impaired oral motor control, or socially disabling drooling despite conservative measures (behavioral strategies, oral medications). After multidisciplinary evaluation by neurology, otolaryngology, or a head and neck specialist, the decision is made to reduce salivary volume via chemical neurolysis of the major salivary glands.
The clinical workflow: the provider confirms indications, documents prior conservative therapy and informed consent, reviews anticoagulation status, and performs a focused head and neck exam. Under ultrasound guidance in an outpatient procedure suite or ambulatory surgical center, the clinician administers botulinum toxin or another approved sclerosing/chemodenervation agent into the parotid and submandibular glands bilaterally. Post-procedure monitoring is brief; the patient receives instructions for possible dry mouth, dysphagia, or transient facial weakness and schedules follow-up to assess efficacy and plan repeat injections as needed. Typical site of service is an outpatient clinic, procedure room, or ambulatory surgical center.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
50 | Bilateral procedure | Use when services are performed bilaterally and no specific bilateral CPT modifier exists beyond the bilateral concept inherent in the code description. |